I Spent Two Weeks Comparing Every Major UK Weight Loss Treatment Comparison Website. Here's What I Actually Found.
I want to start with a confession.
When I first started looking into private weight loss treatment in the UK, I genuinely thought comparison websites would make this simple. I had used comparison sites for insurance, for flights, for broadband. The logic seemed identical: find the product, enter a few details, see the prices ranked cheapest to most expensive, pick one.
What followed was two weeks of increasingly confused research that taught me something nobody's comparison website seemed designed to tell me: the product I was trying to compare is not comparable in the way I assumed. And most of the platforms built to help me compare it were, at best, showing me about a quarter of the information I actually needed.
This post is my attempt to write up what I learned — specifically what each of the major UK weight loss treatment comparison websites does well, where each one stops short, and what I wish I had known before I started.
Upfront caveat: I am not a doctor. Nothing in this post is medical advice. Everything here is personal research notes from someone who spent too long on comparison websites and wants to save someone else the same confusion.
The Thing That Took Me Way Too Long to Understand
GLP-1 medications Mounjaro, Wegovy, Saxenda are not like most products you might compare online. They do not have a single price. They have a price ladder.
All three treatments use a titration protocol. You start at the lowest dose and increase every four weeks. The price goes up at every step. Mounjaro starts at around £128–£180 for the starter 2.5 mg pen. By the time you reach the 15 mg maintenance dose — which is where many people end up and stay — it costs approximately £249–£375 per month, depending on the pharmacy. That is, in many cases, more than double the starter price.
This matters enormously for comparison websites because the number they show you in the headline is almost always the starter dose price. The "from £128/month" figure you see on most sites refers to the first four weeks. Not month six. Not month twelve. Not the dose you will likely be on for most of your treatment.
I did not understand this when I started. I doubt most people do. And very few comparison websites explain it upfront.
The second thing I did not immediately understand is that the pen price is not always the total cost. Some pharmacies include consultation fees, delivery, and needle costs in the price. Others do not. The difference can be £30–£80 per month on top of the headline figure. Two sites showing identical numbers for the same pen can represent very different actual monthly costs once all components are added.
With that context established — here is what I found when I went through the five major comparison platforms one by one.
Click.Compare: Simple, Honest, and Deliberately Narrow
Click.Compare's homepage says "No bias. No fuss. No fluff." This is, in my experience, an accurate description of what they offer — and also an honest summary of its limitations.
What they do is straightforward. They visit registered UK pharmacy websites weekly, record prices for each drug and dosage, and present them in a clean comparison table. They make a deliberate choice to show average prices across doses rather than just the cheapest starter price, which is a more honest approach than most platforms take. They include pharmacy reviews and basic registration checks. And they are clear — genuinely clear, not in a buried-disclaimer way — that they are not medical professionals and are not recommending any medication.
I found Click.Compare genuinely useful as a price sanity check. When I wanted to know roughly what the market looked like for a specific dose without wading through multiple pharmacy sites, it gave me that quickly and without any particular agenda.
What it did not give me: any explanation of what I was comparing, why prices varied across the dose schedule, whether the pharmacies I was looking at were safe to use, whether I might qualify for NHS treatment instead, or what to expect from treatment beyond the price. It assumed I arrived informed. I did not.
For someone who has already done the research and just needs a price check: genuinely useful. For someone at the beginning of the research process: it starts in the middle of the story.
MedEazy: The Daily Updater With More Context Than You Expect
MedEazy surprised me. I went in expecting another price list and came out thinking it was one of the more genuinely useful tools in the market.
The daily price updates are the first differentiator. After the significant Mounjaro price increase in late 2025, platforms that update weekly or monthly were showing outdated figures for weeks. MedEazy's daily refresh means you are looking at pricing that is, at most, 24 hours old — which in a dynamic market matters considerably.
The per-dose page structure also works well in practice. Each medication has its own dedicated page, and within each page you can look at individual dose strengths separately rather than getting a blended average. Knowing what Mounjaro 7.5 mg costs across providers right now is a different and more useful piece of information than knowing the average across all doses.
What genuinely impressed me was the combination of Trustpilot ratings and GPhC registration status in the same view as the pricing. Most comparison sites treat reputation as a secondary lookup — something you go and find separately if you are thorough enough. MedEazy puts it next to the price, which is where it belongs. A pharmacy with a 3.9 Trustpilot score is not offering the same product as a 4.9-rated competitor, even if the pen costs the same.
The discount code tracking is useful if you want to find the best available deal on a specific pen. I was less certain it was pointing me toward the best available provider overall — but for pure price optimisation, it does what it says.
What MedEazy does not do is explain what you are comparing. The clinical layer — mechanism, side effects, what to expect, lifestyle context, NHS eligibility — is not there. It is a price intelligence tool that is better than most. It is not a platform for someone who needs to understand the decision before they can evaluate the options.
Monj: The Most Rigorous Price Verification I Found Anywhere
Monj does something that none of the other platforms I reviewed do: they simulate actual checkouts.
Rather than pulling prices from pharmacy product pages, the Monj team goes through the full purchase flow for every pen strength at every provider — including the consultation stage, the delivery selection, and the final checkout total — to surface fees that do not appear in advertised prices.
This sounds like a detail. It is not. The gap between what a pharmacy advertises and what you are charged at checkout is one of the most significant practical problems in this market. Hidden consultation fees, premium delivery charges, dispensing fees that appear only at the final stage — these can add £30–£80 to a monthly cost that looked very different at the price-comparison stage. Monj's checkout simulation approach is the most direct solution to this problem I have encountered.
The three-view pricing structure — discounted prices with active codes, standard prices without codes, and maintenance-stage pricing — is also the most sophisticated presentation of price information I found. Seeing what treatment costs at the maintenance dose is fundamentally different from seeing the starter price, and Monj makes both visible.
Where Monj fell short for me: it is heavily focused on Mounjaro. Wegovy and Saxenda are present but clearly not the primary focus. Clinical education is minimal. And as a first stop for someone who does not know much about GLP-1 treatment, it assumes more background knowledge than most people arrive with.
For pure Mounjaro price verification at the checkout level: the best I found. As a starting point for understanding the treatment decision: not the right tool.
WegoCompare: The NHS Context Is Genuinely Useful
WegoCompare is doing something slightly different from the other platforms — it is specifically addressing the interface between NHS eligibility and private cost, particularly for Wegovy.
The question "do I qualify for this on the NHS before I consider paying privately?" is one that most comparison platforms ignore entirely. For someone with a BMI above 30 and a weight-related health condition, the answer might well be "yes, technically" — but the practical reality of NHS GLP-1 access in 2026 is that the phased rollout and local commissioning constraints mean most eligible patients are still waiting or unable to access it through NHS pathways.
WegoCompare navigates this honestly. It explains the NICE approval status, the qualifying conditions, the BMI thresholds, and the practical gap between policy and access. This is information that can meaningfully change a research decision — someone who might pursue private prescribing without knowing NHS access exists could, with this context, first explore whether they qualify and whether the NHS route is viable for them locally.
For Wegovy specifically and for the NHS angle: genuinely useful and more thorough than any other platform I reviewed. As a general-purpose weight loss treatment comparison platform: too narrow. Mounjaro and Saxenda coverage is limited, there is no multi-pharmacy live price comparison, and clinical depth beyond eligibility is not substantial.
Healthwise360: The Platform That Answers More of the Right Questions
Healthwise360 took me longer to get through than the others. Not because it is complicated, but because it has substantially more to go through.
The comparison hub at Mounjaro vs Wegovy vs Saxenda covers all three treatments across all dose strengths, drawing from 64 GPhC-registered pharmacies. The filter system — you can set a minimum Trustpilot threshold, select a specific dose, and sort by price or reputation — is the most usable interface I found. It is the only platform where I could ask "show me the pharmacies with at least 4.8 stars on Trustpilot for the 7.5 mg Mounjaro dose" and get a relevant, filtered answer.
The GPhC verification guide is something none of the other platforms offer: a practical explanation of how to check any pharmacy's registration independently, not just a statement that they have done the checking on your behalf. That distinction matters. A platform that teaches you to verify independently is giving you a transferable skill. A platform that simply tells you they have verified leaves you reliant on their curation.
The treatment guides are the most complete independent clinical education I found outside of NHS or manufacturer documentation. What is Mounjaro, What is Wegovy, and What is Saxenda — each covering mechanism, clinical trial results, eligibility context, and practical considerations. Safety content covering fake pharmacy warnings, GP notification, KwikPen disposal and travel. Lifestyle content covering diet, sleep, exercise, plateau management, and the realistic expectations that tend to be absent from manufacturer information.
The tools are unique to Healthwise360 in this space. The BMI calculator includes NHS-aligned category context and treatment eligibility implications — not just a number but a contextualised result. The Mounjaro click calculator is the kind of practical tool that helps with the actual day-to-day experience of being on treatment, not just the decision to start it.
The cheapest options hub gives verified lowest-cost providers at a glance. Location content covers major UK cities for local search relevance.
Where it falls short relative to the other platforms: it does not track individual discount codes in the depth that MedEazy or Click.Compare do. Monj's checkout simulation methodology for hidden fee detection is more granular at the transaction level. My conclusion was that the right research approach uses Healthwise360 as the framework and educational starting point, then cross-references specific pen prices against Monj or MedEazy for checkout-verified current figures before committing to a provider.
The Checklist I Wish I Had Started With
If I were starting this research again, here is the seven-question checklist I would run any comparison platform through before deciding how much to trust its data:
Does it show prices at every dose step — not just the starter? If not, the "from" figure is not useful for budget planning.
Does it disclose consultation, delivery, and programme fees alongside the pen price? If not, you are comparing incomplete numbers.
Does it verify GPhC registration and show you how to check independently? The GPhC register is public. You should be able to verify any pharmacy yourself.
Does it show Trustpilot ratings next to prices — not just as a separate lookup? Reputation data belongs next to price data, not in a different place.
Does it explain NHS eligibility? For Mounjaro and Wegovy, NHS access exists. If a platform does not mention this, it is missing context that might change your decision.
Does it explain what the treatments actually are? Mechanism, side effects, titration expectations. If the answer is no, you need to find this information elsewhere before the price comparison stage.
Does it disclose its commercial relationships with providers? Referral fees exist in this market. They should be disclosed. If they are not, treat rankings with appropriate scepticism.
The platforms that pass most of these questions give you comparison information. The platforms that pass only the first one give you a price list. Both are useful. Only one gives you what you actually need.
What I Think Is Actually Happening in This Market
The UK private GLP-1 comparison market has grown very fast. Mounjaro's MHRA approval in 2023 and the subsequent NICE guidance for both Mounjaro and Wegovy triggered a rapid expansion of private prescribing, and comparison platforms followed the market.
The problem is that the incentive structure for most comparison platforms points toward conversion, not comprehension. If a platform earns money when users click through to a pharmacy, the optimal platform design is one that presents prices attractively and removes friction from the click — not one that provides clinical education, surfaces safety concerns, or explains that a more expensive provider might be the better choice.
This is not a conspiracy. It is just what commercial incentives produce when they are not counterbalanced by a genuine commitment to user education.
The platforms that do the latter — that treat comparison as a complete information service rather than a price-listing function — are doing something harder, and producing something more valuable. Healthwise360's approach of combining price comparison with GPhC verification education, clinical guides, safety content, lifestyle context, and interactive tools is the closest thing I found to what responsible comparison looks like in this market.
It is also, not coincidentally, the platform I found myself returning to most during two weeks of research — because it was the only one that consistently answered the question I actually had, rather than the question it was easiest to answer.
Bottom Line
Five comparison platforms. Very different answers to the question of what comparison means.
Click.Compare: clean, honest price reference. Narrow by design. MedEazy: daily-updated per-dose pricing with reputation data. Stronger than it looks. Monj: the most rigorous checkout verification in the market. Mounjaro-specialist. WegoCompare: the best NHS eligibility context. Wegovy-focused. Healthwise360: the most complete platform. Educational framework plus price comparison plus tools.
None of them is perfect. The most complete research process uses Healthwise360 as the foundation, Monj or MedEazy for final price verification, and independent GPhC registration checks before committing to any provider.
And whatever platform you use: check the per-dose pricing across the full titration schedule, not just the starter. The number in the headline is not the number that matters most.
For informational purposes only. Not medical advice. No commercial affiliations with any platform, pharmacy, or provider mentioned. Prices approximate and subject to change.
Comments
Post a Comment